Zylox-Tonbridge Issues Positive Profit Alert, Expects Over RMB 115 Million in 1H 2025 Net Profit
The strong performance was primarily driven by the continued expansion of the Company's neurovascular and peripheral vascular intervention businesses, as well as further improvements in operational efficiency. Key products such as the Kylin™ Flow Diverter, neurovascular guidewires, UltraFree® Drug-Coated PTA Balloon Catheter, and Zylox Octoplus™
In addition to commercial expansion, Zylox-Tonbridge also accelerated the launch of innovative products. In the first half of 2025, the ZYLOX Eagle™ Peripheral Thrombus aspiration system received marketing approval from
The Company also made notable progress in international markets. Several core products obtained regulatory approvals and achieved initial commercial sales in key emerging markets in
Looking ahead, Zylox-Tonbridge remains committed to its mission of "Innovation for Quality Life". The Company will continue to invest in medical technology innovation and strive to provide high-quality, and affordable solutions for patients worldwide. By advancing the adoption of innovative technologies, Zylox-Tonbridge aims to contribute to the sustainable development of the global healthcare ecosystem.
View original content:https://www.prnewswire.com/news-releases/zylox-tonbridge-issues-positive-profit-alert-expects-over-rmb-115-million-in-1h-2025-net-profit-302511762.html
SOURCE ZYLOX-TONBRIDGE